Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics.

ABSTRACT: A hallmark of cancer is cell death evasion, underlying suboptimal responses to chemotherapy, targeted agents, and immunotherapies. The approval of the antiapoptotic BCL2 antagonist venetoclax has finally validated the potential of targeting apoptotic pathways in patients with cancer. Nevertheless, pharmacologic modulators of cell death have shown markedly varied responses in preclinical and clinical studies. Here, we review emerging concepts in the use of this class of therapies. Building on these observations, we propose that treatment-induced changes in apoptotic dependency, rather than pretreatment dependencies, will need to be recognized and targeted to realize the precise deployment of these new pharmacologic agents.

Significance

Targeting antiapoptotic family members has prove

SUBMITTER: Montero J 

PROVIDER: S-EPMC9306285 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature